Sun Pharmaceutical Industries Balance Sheet Health
Financial Health criteria checks 6/6
Sun Pharmaceutical Industries has a total shareholder equity of ₹724.9B and total debt of ₹23.6B, which brings its debt-to-equity ratio to 3.3%. Its total assets and total liabilities are ₹921.0B and ₹196.1B respectively. Sun Pharmaceutical Industries's EBIT is ₹129.7B making its interest coverage ratio -12.3. It has cash and short-term investments of ₹261.2B.
Key information
3.26%
Debt to equity ratio
₹23.62b
Debt
| Interest coverage ratio | -12.3x |
| Cash | ₹261.23b |
| Equity | ₹724.86b |
| Total liabilities | ₹196.15b |
| Total assets | ₹921.01b |
Recent financial health updates
Recent updates
Earnings Miss: Sun Pharmaceutical Industries Limited Missed EPS By 22% And Analysts Are Revising Their Forecasts
Aug 04
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Will Pay A Dividend Of ₹5.50
Jun 27What Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Not Telling You
Jun 26Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Due To Pay A Dividend Of ₹5.50
May 25Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Well Worth Watching
May 15Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Shares May Have Run Too Fast Too Soon
Feb 23Analysts Are Updating Their Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Estimates After Its Third-Quarter Results
Feb 05Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 04Here's Why Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has Caught The Eye Of Investors
Jan 29Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18
Robust Product Pipeline And Market Expansion Drive Growth Amidst Challenges
U.S. and India sales, driven by market leadership and product launches, enhance revenue growth and net margins via economies of scale.Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Financial Position Analysis
Short Term Liabilities: SUNPHARMA's short term assets (₹526.2B) exceed its short term liabilities (₹181.9B).
Long Term Liabilities: SUNPHARMA's short term assets (₹526.2B) exceed its long term liabilities (₹14.2B).
Debt to Equity History and Analysis
Debt Level: SUNPHARMA has more cash than its total debt.
Reducing Debt: SUNPHARMA's debt to equity ratio has reduced from 15.4% to 3.3% over the past 5 years.
Debt Coverage: SUNPHARMA's debt is well covered by operating cash flow (595.7%).
Interest Coverage: SUNPHARMA earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/04 17:46 |
| End of Day Share Price | 2025/09/04 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sun Pharmaceutical Industries Limited is covered by 81 analysts. 37 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashwin Mehta | Ambit Capital |
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |